Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-11T05:23:55.083Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of tumour volume as a prognostic factor in non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy

Published online by Cambridge University Press:  15 February 2019

R. Joyce Open the ORCID record for R. Joyce [Opens in a new window] ,
G. O’Boyle ,
R. L. McDermott  and
C. Small
R. Joyce*
Affiliation:
Department of Radiation Oncology, University Hospital Galway, Galway, Ireland National University of Ireland, Galway, Ireland
G. O’Boyle
Affiliation:
Department of Radiation Oncology, University Hospital Galway, Galway, Ireland
R. L. McDermott
Affiliation:
Department of Radiation Oncology, University Hospital Galway, Galway, Ireland
C. Small
Affiliation:
Department of Radiation Oncology, University Hospital Galway, Galway, Ireland
*
Author for correspondence: Dr Ronan Joyce, Radiation Oncology Department, University Hospital Galway, Newcastle Road Galway, Galway, H91 YR71, Ireland. Tel: +35391524222. E-mail: Ronanajoyce@gmail.com, Ronan.Joyce@hse.ie
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

It has been shown that patients with a greater tumour volume have poorer outcomes following definitive radiotherapy but its exact role remains unclear. The purpose of this study is to investigate the role of tumour volume as a prognostic indicator in non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy in a single institution over 10 years.

Methods

In total, 167 patients with NSCLC treated by definitive (chemo)radiotherapy were retrospectively reviewed between 2006 and 2015. Patient demographics, disease characteristics and tumour volume parameters were collected. Univariate analyses were carried out using Kaplan–Meier survival curves to assess the association of potential prognostic factors with the primary endpoints of overall survival (OS) rates and locoregional recurrence rates. Multivariate analyses were carried out using a Cox regression method.

Results

The median total tumour volume (TTV), defined as the gross tumour volume plus the volume of involved nodes, was 103 cm3. Patients were divided into small and large tumour groups based on this median. OS rates at 1, 3 and 5 years for smaller volumes were 69%, 24% and 13% and for larger volumes 48%, 14% and 8%, respectively. On univariate survival analyses larger TTV was significantly associated with poorer OS (p = 0·019). The concurrent use of chemotherapy significantly improved survival (p = 0·026). Nodal involvement (p = 0·03) and Eastern Cooperative Oncology Group performance status (p < 0·001) were also significant independent prognostic factors of OS. On multivariate analysis TTV was strongly predictive of survival (p = 0·03; hazard ratio 1·702, 95% confidence interval 1·198–2·415). There was no association between nodal volume, tumour stages, overall stage, age, histology and radiation dose with any of the primary endpoints.

Conclusion

TTV is a significant prognostic factor in patients with advanced NSCLC treated by radical radiotherapy. In this cohort of patients TTV is more reliable at predicting survival than T stage and overall stage.

Keywords

non-small cell lung canceroverall survivalprognosisradiotherapytumour volume
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 18 , Issue 3 , September 2019 , pp. 218 - 224
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Joyce R, O’Boyle G, McDermott RL, Small C. (2019) The role of tumour volume as a prognostic factor in non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy. Journal of Radiotherapy in Practice18: 218–224. doi: 10.1017/S1460396919000037

References

1. WHO | Cancer: World Health Organization. 2017. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed on 15th May 2017.Google Scholar
2. National Cancer Registry Ireland. Essential information on cancer in Ireland. 2017. http://www.ncri.ie/ Accessed on 15th May 2017.Google Scholar
3. Warner, A, Dahele, M, Hu, B et al. Factors associated with early mortality in patients treated with concurrent chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2016; 94 (3): 612–620.10.1016/j.ijrobp.2015.11.030Google Scholar
4. Kim, Y H, Ahn, S J, Kim, Y C et al. Predictive factors for survival and correlation to toxicity in advanced stage III non-small cell lung cancer patients with concurrent chemoradiation. Jpn J Clin Oncol 2016; 46 (2): 144–151.Google Scholar
5. Berghmans, T, Paesmans, M, Sculier, J P. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 2011; 3 (3): 127–138.10.1177/1758834011401951Google Scholar
6. Brundage, M D, Davies, D, Mackillop, W J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122 (3): 1037–1057.10.1378/chest.122.3.1037Google Scholar
7. Rodrigues, G, Choy, H, Bradley, J et al. Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 2015; 5 (3): 141–148.10.1016/j.prro.2015.02.012Google Scholar
8. Eberhardt, W E, De Ruysscher, D, Weder, W et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015; 26 (8): 1573–1588.10.1093/annonc/mdv187Google Scholar
9. Yu, Y, Guan, H, Xing, L G, Xiang, Y B. Role of gross tumor volume in the prognosis of non-small cell lung cancer treated with 3D conformal radiotherapy: a meta-analysis. Clin Ther 2015; 37 (10): 2256–2266.10.1016/j.clinthera.2015.07.014Google Scholar
10. Koo, T R, Moon, S H, Lim, Y J et al. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiat Oncol (London, England) 2014; 9: 283–286.10.1186/s13014-014-0283-6Google Scholar
11. Soliman, M, Yaromina, A, Appold, S et al. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol 2013; 106 (3): 299–304.10.1016/j.radonc.2012.12.008Google Scholar
12. Ball, D L, Fisher, R J, Burmeister, B H et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 2013; 106 (3): 305–311.10.1016/j.radonc.2012.12.003Google Scholar
13. Alexander, B M, Othus, M, Caglar, H B, Allen, A M. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011; 79 (5): 1381–1387.10.1016/j.ijrobp.2009.12.060Google Scholar
14. Werner-Wasik, M, Swann, R S, Bradley, J et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I–II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70 (2): 385–390.10.1016/j.ijrobp.2007.06.034Google Scholar
15. Dehing-Oberije, C, De Ruysscher, D, van der Weide, H et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70 (4): 1039–1044.10.1016/j.ijrobp.2007.07.2323Google Scholar
16. Stinchcombe, T E, Morris, D E, Moore, D T et al. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. Lung Cancer (Amsterdam, The Netherlands) 2006; 52 (1): 67–74.10.1016/j.lungcan.2005.11.008Google Scholar
17. Basaki, K, Abe, Y, Aoki, M, Kondo, H, Hatayama, Y, Nakaji, S. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 2006; 64 (2): 449–454.10.1016/j.ijrobp.2005.07.967Google Scholar
18. De Petris, L, Lax, I, Sirzen, F, Friesland, S. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. Med Oncol (Northwood, London, England) 2005; 22 (4): 375–381.10.1385/MO:22:4:375Google Scholar
19. Willner, J, Baier, K, Caragiani, E, Tschammler, A, Flentje, M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52 (2): 382–389.10.1016/S0360-3016(01)01823-5Google Scholar
20. Etiz, D, Marks, L B, Zhou, S M et al. Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 53 (4): 835–846.10.1016/S0360-3016(02)02814-6Google Scholar
21. Bradley, J D, Ieumwananonthachai, N, Purdy, J A et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52 (1): 49–57.10.1016/S0360-3016(01)01772-2Google Scholar
22. Martel, M K, Strawderman, M, Hazuka, M B, Turrisi, A T, Fraass, B A, Lichter, A S. Volume and dose parameters for survival of non-small cell lung cancer patients. Radiother Oncol 1997; 44 (1): 23–29.10.1016/S0167-8140(97)00081-9Google Scholar
23. Baumann, M, Krause, M, Thames, H, Trott, K, Zips, D. Cancer stem cells and radiotherapy. Int J Radiat Biol 2009; 85 (5): 391–402.10.1080/09553000902836404Google Scholar
24. Baumann, M, Dorr, W, Petersen, C, Krause, M. Repopulation during fractionated radiotherapy: much has been learned, even more is open. Int J Radiat Biol 2003; 79 (7): 465–467.10.1080/0955300031000160259Google Scholar
25. Petersen, C, Zips, D, Krause, M et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001; 51 (2): 483–493.10.1016/S0360-3016(01)01686-8Google Scholar
26. Bentzen, S M, Thames, H D. Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 1996; 36 (1): 247–251.10.1016/S0360-3016(96)00242-8Google Scholar
27. Maguire, J, Khan, I, McMenemin, R et al. SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer (Oxford, England: 1990) 2014; 50 (17): 2939–2949.10.1016/j.ejca.2014.07.009Google Scholar
28. Edge S B, American Joint Committee on Cancer et al. “Lung” AJCC cancer staging manual 7th edition. New York: Springer, 2010: 253–270.Google Scholar
29. Greene, F, Balch, C, Haller, D, Morrow, M. AJCC Cancer Staging Manual, 6th edition. New York; NY: Springer, 2002.10.1007/978-1-4757-3656-4Google Scholar
30. Albain, K S, Crowley, J J, Turrisi, A T 3rd et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20 (16): 3454–3460.10.1200/JCO.2002.03.055Google Scholar
31. Dehing-Oberije, C, Aerts, H, Yu, S et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011; 81 (2): 360–368.10.1016/j.ijrobp.2010.06.011Google Scholar
32. Oberije, C, De Ruysscher, D, Houben, R et al. A validated prediction model for overall survival from stage III non-small cell lung cancer: toward survival prediction for individual patients. Int J Radiat Oncol Biol Phys 2015; 92 (4): 935–944.10.1016/j.ijrobp.2015.02.048Google Scholar
33. Vansteenkiste, J, De Ruysscher, D, Eberhardt, W E et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (suppl 6): vi89–98.10.1093/annonc/mdt241Google Scholar
34. Baumann, M, Krause, M, Hill, R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8 (7): 545–554.Google Scholar
35. Baumann, M, Dubois, W, Suit, H D. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res 1990; 123 (3): 325–330.10.2307/3577740Google Scholar
36. Amin M B, Edge S B, American Joint Committee on Cancer et al. AJCC cancer staging manual, 8th edition. New York: Springer, 2017.Google Scholar
37. Bradley, J D, Paulus, R, Komaki, R et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16 (2): 187–199.10.1016/S1470-2045(14)71207-0Google Scholar
38. Chun, S G, Hu, C, Choy, H et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017; 35 (1): 56–62.10.1200/JCO.2016.69.1378Google Scholar